ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
A

ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhibitor Treatment-Naïve Myelofibrosis

By ASH 2021 Conference Coverage on VuMedi FEATURING Abdulraheem Yacoub
By ASH 2021 Conference Coverage on VuMedi FEATURING Abdulraheem Yacoub
67 views
December 22, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Featured Video

19:39
Pfizer Hematology

Making the First Chance Count: Manuel

Feat. A. Ip
MDS and MPN
06:20

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

115 views
07:13

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

156 views
10:26

ASH 2021 Updates on a Pooled Analysis of the COMFORT-I & II Studies:…

ASH 2021 Conference Coverage on VuMedi

S. Verstovsek

311 views
06:04

ASH 2021 Clinical and Pathological Characteristics of Hypocellular M…

ASH 2021 Conference Coverage on VuMedi

K. Kim

152 views
05:14

ASH 2021 NGS Evaluation of the EQoL-MDS Trial: Preliminary Analysis …

ASH 2021 Conference Coverage on VuMedi

E. Oliva

118 views
11:04

ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with …

ASH 2021 Conference Coverage on VuMedi

J. Bewersdorf

123 views
06:52

ASH 2021: A Phase 3 Study of Hepcidin Mimetic Rusfertide in Patients…

ASH 2021 Conference Coverage on VuMedi

S. Verstovsek

97 views
11:17

ASH 2021 Updates on the Management of Polycythemia Vera

ASH 2021 Conference Coverage on VuMedi

A. Kuykendall

39 views
04:45

ASH 2021 on LR-MDS: Factors Predicting Progression to HR-MDS and AML…

ASH 2021 Conference Coverage on VuMedi

A. Jain

98 views
08:59

ASH 2021 Update on the Outcomes of Therapy-Related Myeloid Neoplasms…

ASH 2021 Conference Coverage on VuMedi

M. Shah

12 views
08:12

ASH 2021 Efficacy and Safety of Parsaclisib+Ruxolitinib Combination …

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

13 views
08:30

ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targete…

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

70 views
05:32

ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhib…

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

67 views
08:15

ASH 2021 Highlights in MPN

ASH 2021 Conference Coverage on VuMedi

P. Bose

249 views
15:25

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

ASH 2021 Conference Coverage on VuMedi

M. Kremyanskaya

88 views
10:43

ASH 2021 Final Results of a Phase 2 Study of Sotatercept for Anemia …

ASH 2021 Conference Coverage on VuMedi

P. Bose

98 views
05:06

Positioning Fedratinib in the Treatment Strategy of Myelofibrosis

ASH 2021 Conference Coverage on VuMedi

F. Passamonti

141 views
13:17

ASH 2021 Molecular Responses in Treatment-Naïve HR-MDS Patients Trea…

ASH 2021 Conference Coverage on VuMedi

J. Garcia

75 views
12:03

ASH 2021 Highlights on Efficacy and Safety of Sabatolimab for Patien…

ASH 2021 Conference Coverage on VuMedi

A. Brunner

72 views
06:27

ASH 2021 Updates on the Phase 2 Study of Bomedemstat (IMG-7289) In P…

ASH 2021 Conference Coverage on VuMedi

H. Gill

477 views
07:56

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

52 views
10:27

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

Richard T. Silver

329 views
10:44

A Real-World Evaluation of the Association Between Elevated Blood Co…

Aaron Gerds

1.1K views
15:40

ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemi…

ASH 2021 Conference Coverage on VuMedi

A. Tefferi

437 views
05:15

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

617 views